CY1108963T1 - MIDDLE-CHAIN OIL FAT ACIDS, GLYCERIDES AND ANALOGS AS CIRCULAR INDICATORS - Google Patents

MIDDLE-CHAIN OIL FAT ACIDS, GLYCERIDES AND ANALOGS AS CIRCULAR INDICATORS

Info

Publication number
CY1108963T1
CY1108963T1 CY20091100397T CY091100397T CY1108963T1 CY 1108963 T1 CY1108963 T1 CY 1108963T1 CY 20091100397 T CY20091100397 T CY 20091100397T CY 091100397 T CY091100397 T CY 091100397T CY 1108963 T1 CY1108963 T1 CY 1108963T1
Authority
CY
Cyprus
Prior art keywords
glycerides
analogs
oil fat
chain oil
fat acids
Prior art date
Application number
CY20091100397T
Other languages
Greek (el)
Inventor
Christopher Penney
Lyne Gagnon
Pierre Laurin
Boulos Zacharie
Original Assignee
Prometic Biosciences Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Prometic Biosciences Inc. filed Critical Prometic Biosciences Inc.
Publication of CY1108963T1 publication Critical patent/CY1108963T1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Emergency Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

Χρήση μιας σύνθεσης που περιλαμβάνει μια ένωση οποιουδήποτε των τύπων I, II, IIa, III και IIIa ή συνδυασμό αυτών, όπου έκαστο R1 ανεξαρτήτως είναι C7-11 αλκύλ, τα Α και Β ανεξαρτήτως είναι Η ή CO R1, το R2 είναι Η ή C1-4 αλκύλ, το Μ είναι μονοκατιόν μετάλλου (k = 1) ή δικατιόν (k = 2), το Υ είναι Ο ή ΝΗ και το Ζ είναι Ο, ΝΗ, CH2O ή ένας δεσμός για τη βιομηχανική κατασκευή ενός φαρμάκου για διέγερση ερυθροποίησης. Κατά προτίμηση, η σύνθεση περαιτέρω περιλαμβάνει ανθρώπινη ερυθροποιητίνη.Use of a composition comprising a compound of any of the formulas I, II, IIa, III and IIIa or a combination thereof, wherein each R1 independently is C7-11 alkyl, A and B independently are H or CO R1, R2 is H or C1 -4 alkyl, M is a metal (k = 1) or bicyclic (k = 2), Y is O or NH and Z is O, NH, CH 2 O or a bond for the manufacture of a medicament for inducing erythropoiesis. Preferably, the composition further comprises human erythropoietin.

CY20091100397T 2003-02-07 2009-04-06 MIDDLE-CHAIN OIL FAT ACIDS, GLYCERIDES AND ANALOGS AS CIRCULAR INDICATORS CY1108963T1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US44545403P 2003-02-07 2003-02-07
EP04708802A EP1592416B1 (en) 2003-02-07 2004-02-06 Medium-chain length fatty acids, glycerides and analogues as stimulators of erythropoiesis

Publications (1)

Publication Number Publication Date
CY1108963T1 true CY1108963T1 (en) 2014-07-02

Family

ID=32850990

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20091100397T CY1108963T1 (en) 2003-02-07 2009-04-06 MIDDLE-CHAIN OIL FAT ACIDS, GLYCERIDES AND ANALOGS AS CIRCULAR INDICATORS

Country Status (28)

Country Link
US (1) US9682054B2 (en)
EP (1) EP1592416B1 (en)
JP (1) JP5390070B2 (en)
KR (1) KR101120775B1 (en)
CN (1) CN100427081C (en)
AP (1) AP2005003367A0 (en)
AR (1) AR043120A1 (en)
AT (1) ATE419846T1 (en)
AU (1) AU2004210193B2 (en)
BR (1) BRPI0407276A (en)
CA (1) CA2515160C (en)
CY (1) CY1108963T1 (en)
DE (2) DE602004018902D1 (en)
DK (1) DK1592416T3 (en)
EA (1) EA009939B1 (en)
ES (1) ES2255467T3 (en)
IL (1) IL170057A (en)
JO (1) JO2705B1 (en)
MA (1) MA27664A1 (en)
MX (1) MXPA05008382A (en)
MY (1) MY140913A (en)
NO (1) NO334085B1 (en)
NZ (1) NZ541593A (en)
PT (1) PT1592416E (en)
SI (1) SI1592416T1 (en)
TN (1) TNSN05189A1 (en)
WO (1) WO2004069237A1 (en)
ZA (1) ZA200506246B (en)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL223348B1 (en) 2001-04-18 2016-10-31 Prometic Biosciences Inc Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors
US20050232981A1 (en) * 2004-04-15 2005-10-20 Ben-Sasson Shmuel A Compositions capable of facilitating penetration across a biological barrier
US20070219131A1 (en) * 2004-04-15 2007-09-20 Ben-Sasson Shmuel A Compositions capable of facilitating penetration across a biological barrier
EP1771470B1 (en) 2004-07-23 2013-06-26 Acceleron Pharma Inc. Actrii receptor polypeptides, methods and compositions
ZA200701781B (en) * 2004-09-03 2008-11-26 Prometic Biosciences Inc Substituted purinyl derivatives with immunomodulator and chemoprotective activity and use alone or with medium-chain length fatty acids or glycerides
US8071580B2 (en) 2004-10-01 2011-12-06 Prometic Biosciences Inc. Medium-chain length fatty alcohols as stimulators of hematopoiesis
ES2376201T3 (en) * 2004-10-01 2012-03-09 Prometic Biosciences Inc. GREAT ALCOHOLS OF AVERAGE CHAIN LENGTH AS STIMULATORS OF HEMATOPOYESIS.
KR20190006086A (en) 2005-11-23 2019-01-16 악셀레론 파마 인코포레이티드 Activin-actrπa antagonists and uses for promoting bone growth
US8128933B2 (en) 2005-11-23 2012-03-06 Acceleron Pharma, Inc. Method of promoting bone growth by an anti-activin B antibody
US8895016B2 (en) 2006-12-18 2014-11-25 Acceleron Pharma, Inc. Antagonists of activin-actriia and uses for increasing red blood cell levels
EP2111229B1 (en) 2007-02-01 2013-04-10 Acceleron Pharma, Inc. Pharmaceutical compositions comprising Activin-ActRIIA antagonists for use in preventing or treating breast cancer metastasis or breast cancer related bone loss
TWI548647B (en) 2007-02-02 2016-09-11 艾瑟勒朗法瑪公司 Variants derived from actriib and uses therefor
EP2120999B1 (en) 2007-02-09 2012-08-29 Acceleron Pharma, Inc. Pharmaceutical compositions comprising Activin-ActRIIA antagonists and use thereof in preventing or treating multiple myeloma
CN103877564A (en) 2007-09-18 2014-06-25 阿塞勒隆制药公司 Activin-actriia antagonists and uses for decreasing or inhibiting fsh secretion
CN101878028A (en) * 2007-11-02 2010-11-03 普罗米蒂克生物科学公司 Medium-chain length fatty acids and glycerides as nephroprotection agents
DK2231166T3 (en) * 2007-12-19 2013-06-24 Prometic Biosciences Inc Medium-chain fatty acids, salts and triglycerides in combination with gemcitabine for the treatment of pancreatic cancer
US8216997B2 (en) 2008-08-14 2012-07-10 Acceleron Pharma, Inc. Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators
LT3750552T (en) 2008-08-14 2023-06-26 Acceleron Pharma Inc. Gdf traps
EP2343982B1 (en) 2008-09-17 2017-03-22 Chiasma Inc. Pharmaceutical compositions and related methods of delivery
BRPI1010587A2 (en) 2009-06-08 2019-04-09 Acceleron Pharma Inc. Methods to Increase Thermogenic Adipocytes
EP2440577A4 (en) 2009-06-12 2013-01-23 Acceleron Pharma Inc Truncated actriib-fc fusion proteins
RU2642302C1 (en) * 2009-08-13 2018-01-24 Акселерон Фарма Инк. Combined administration of gdf traps and erythropoetin receptor activators for increasing content of erythrocytes
US8710016B2 (en) 2009-11-17 2014-04-29 Acceleron Pharma, Inc. ActRIIB proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy
JP2014502260A (en) 2010-11-08 2014-01-30 アクセルロン ファーマ， インコーポレイテッド ACTRIIA binders and uses thereof
TWI572352B (en) * 2012-03-01 2017-03-01 波麥堤克藥學Ｓｍｔ有限公司 Method for the preparation of triglycerides of medium-chain length fatty acids
MX366336B (en) 2012-11-02 2019-07-05 Celgene Corp Activin-actrii antagonists and uses for treating bone and other disorders.
CN102973922B (en) * 2012-12-18 2016-02-03 华东理工大学 A kind of application of fusion rotein
BR122023023170A2 (en) 2014-06-13 2024-02-20 Acceleron Pharma Inc. USE OF AN ACTRII ANTAGONIST IN THE TREATMENT OR PREVENTION OF SKIN ULCERS ASSOCIATED WITH BETA-THALASSEMIA
MA41052A (en) 2014-10-09 2017-08-15 Celgene Corp TREATMENT OF CARDIOVASCULAR DISEASE USING ACTRII LIGAND TRAPS
AU2015358469B2 (en) 2014-12-03 2021-05-27 Acceleron Pharma Inc. Activin-ActRII antagonists and uses for treating anemia
CA2975599A1 (en) 2015-02-03 2016-08-11 Chiasma Inc. Method of treating diseases
US20170021029A1 (en) * 2015-04-15 2017-01-26 Jeffrey Charles Raber Topical formulations and uses
US11141457B1 (en) 2020-12-28 2021-10-12 Amryt Endo, Inc. Oral octreotide therapy and contraceptive methods

Family Cites Families (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4871768A (en) 1984-07-12 1989-10-03 New England Deaconess Hospital Corporation Dietary supplement utilizing ω-3/medium chain trigylceride mixtures
US6054441A (en) 1987-10-28 2000-04-25 Pro-Neuron, Inc. Oxypurine nucleosides and their congeners, and acyl derivatives thereof, for improvement of hematopoiesis
US5011852A (en) 1988-07-25 1991-04-30 Applied Analytical Industries, Inc. Liquid oral pharmaceutical compositions of non-steroidal anti-inflammatory drugs
JP3014119B2 (en) * 1990-05-28 2000-02-28 雪印乳業株式会社 Erythropoietic agents for rectal administration
JP3249147B2 (en) 1990-06-01 2002-01-21 キリン−アムジエン・インコーポレーテツド Oral preparation containing bioactive protein
EP0495187B1 (en) * 1991-01-15 1997-01-22 Hemosphere, Inc. Protein nanomatrixes and method of production
JPH05163160A (en) 1991-12-13 1993-06-29 Snow Brand Milk Prod Co Ltd Nutrient preparation for prevention and treatment of infectious disease caused by immune depression
US5214035A (en) 1992-04-16 1993-05-25 Hoechst-Roussel Agri-Vet Company Thixotropic formulations
US5318781A (en) * 1993-04-06 1994-06-07 Hoffmann-La Roche Inc. Absorption enhancement of antibiotics
US20010003739A1 (en) * 1993-06-24 2001-06-14 Astrazeneca Ab Systemic administration of a therapeutic preparation
US5631219A (en) * 1994-03-08 1997-05-20 Somatogen, Inc. Method of stimulating hematopoiesis with hemoglobin
WO1995030413A1 (en) 1994-05-10 1995-11-16 The Kitasato Institute Hematopoietic stem cell proliferation accelerator
US5470861A (en) 1994-08-04 1995-11-28 Hoffmann-La Roche Inc. Method of promoting hair growth
US5549905A (en) 1994-10-18 1996-08-27 Clintec Nutrition Co. Enternal composition for pediatric patients
JPH08208510A (en) 1994-11-03 1996-08-13 F Hoffmann La Roche Ag Interferon composition
GB9516268D0 (en) 1995-08-08 1995-10-11 Danbiosyst Uk Compositiion for enhanced uptake of polar drugs from the colon
AUPN933396A0 (en) 1996-04-17 1996-05-09 Pfizer Pty Limited Non-aqueuos oral-drench compositions containing avermectin compounds
US5851534A (en) 1996-05-03 1998-12-22 Dynagen, Inc. Methods for prevention and/or treatment of neutropenia
JPH10265380A (en) 1997-03-17 1998-10-06 Bristol Myers Squibb Co Anticancer agent
CA2303200A1 (en) * 1997-09-04 1999-03-11 Brian C. Keller Oral liposomal delivery system
JP4575592B2 (en) * 1997-11-14 2010-11-04 パシラ ファーマシューティカルズ インコーポレーテッド Production of multivesicular liposomes
WO1999025312A1 (en) 1997-11-19 1999-05-27 Hercules Incorporated Fluidized polymer suspensions of cationic polysaccharides in emollients and use thereof in preparing personal care compositions
DE69833333T2 (en) * 1997-11-20 2006-10-19 Jhon, Gil Ja PHARMACEUTICAL COMPOSITION CONTAINING CERVUS NIPPON GERMANIC ACIDS WITH GROWTH STIMULATING ACTIVITY ON HEMATOPOIETIC STEM CELLS AND MEGAKARYOCYTES
ATE271376T1 (en) * 1998-02-23 2004-08-15 Cilag Ag Int LIPOSOMAL ERYTHROPOIETIN DISPERSION
JP4372347B2 (en) 1998-03-11 2009-11-25 あすか製薬株式会社 Effervescent enteric preparation
US6267985B1 (en) 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
CA2385989A1 (en) 1999-09-27 2001-04-05 Andrew Nienstedt Compositions of tocol-soluble therapeutics
US6835750B1 (en) 2000-05-01 2004-12-28 Accera, Inc. Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism II
ATE341331T1 (en) 2000-06-14 2006-10-15 William Leslie Porter LIPIDS TO MODIFY THE DEFENSE SYSTEM
US6967028B2 (en) 2000-07-31 2005-11-22 Mainelab Prolonged release microspheres for injectable administration
IL142535A0 (en) 2001-04-11 2002-03-10 Yeda Res & Dev Pharmaceutical compositions for the treatment of inflammation
PL223348B1 (en) 2001-04-18 2016-10-31 Prometic Biosciences Inc Medium-chain length fatty acids, glycerides and analogues as neutrophil survival and activation factors
US20040052836A1 (en) 2002-09-13 2004-03-18 Li Luk Chiu Pharmaceutical compositions containing at least one stable liposphere having an improved shelf life
US6725510B1 (en) 2003-04-25 2004-04-27 Almetta Clyburn Inclining coffin
CN1839111B (en) 2003-07-25 2010-04-21 普罗米蒂克生物科学公司 Preparation of metal salts of medium-chain fatty acids
ZA200701781B (en) 2004-09-03 2008-11-26 Prometic Biosciences Inc Substituted purinyl derivatives with immunomodulator and chemoprotective activity and use alone or with medium-chain length fatty acids or glycerides
US8071580B2 (en) 2004-10-01 2011-12-06 Prometic Biosciences Inc. Medium-chain length fatty alcohols as stimulators of hematopoiesis

Also Published As

Publication number Publication date
NO20053994L (en) 2005-10-06
US9682054B2 (en) 2017-06-20
AU2004210193A1 (en) 2004-08-19
US20060128800A1 (en) 2006-06-15
CN1753665A (en) 2006-03-29
DE602004018902D1 (en) 2009-02-26
NO334085B1 (en) 2013-12-09
KR101120775B1 (en) 2012-04-18
ES2255467T3 (en) 2009-05-01
NO20053994D0 (en) 2005-08-26
JP5390070B2 (en) 2014-01-15
ZA200506246B (en) 2006-12-27
EP1592416B1 (en) 2009-01-07
MY140913A (en) 2010-01-29
KR20050118671A (en) 2005-12-19
NZ541593A (en) 2009-05-31
PT1592416E (en) 2009-04-03
SI1592416T1 (en) 2009-06-30
BRPI0407276A (en) 2006-01-31
MXPA05008382A (en) 2005-11-04
ES2255467T1 (en) 2006-07-01
CA2515160A1 (en) 2004-08-19
CN100427081C (en) 2008-10-22
DE04708802T1 (en) 2006-06-22
TNSN05189A1 (en) 2007-06-11
WO2004069237A1 (en) 2004-08-19
EA200501267A1 (en) 2006-02-24
AR043120A1 (en) 2005-07-20
JO2705B1 (en) 2014-03-15
EA009939B1 (en) 2008-04-28
AP2005003367A0 (en) 2005-09-30
MA27664A1 (en) 2005-12-01
DK1592416T3 (en) 2009-04-20
ATE419846T1 (en) 2009-01-15
IL170057A (en) 2011-09-27
EP1592416A1 (en) 2005-11-09
AU2004210193B2 (en) 2007-07-12
JP2006516987A (en) 2006-07-13
CA2515160C (en) 2013-01-08

Similar Documents

Publication Publication Date Title
CY1108963T1 (en) MIDDLE-CHAIN OIL FAT ACIDS, GLYCERIDES AND ANALOGS AS CIRCULAR INDICATORS
AR025225A1 (en) PHYSYLOXAZOLIDINONES HETEROCICLIC BICYCLIC REPLACED ANTIBACTERIAL AND PHARMACEUTICAL COMPOSITIONS
DK0639577T3 (en) Phosphonooxymethyl or methylthiomethyl esters of taxane derivatives as antitumor agents
ES2190396T3 (en) NEW AMINO-TRIAZOL COMPOUNDS, THEIR PREPARATION PROCEDURE AND THE PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
FI903331A0 (en) KINAZOLINONER SUBSTITUERADE, VILKA AER ANVAENDBARA SOM ANGIOTENSIN-II-ANTAGONISTER.
UY28572A1 (en) NEW COMPOUNDS
ECSP066898A (en) SELECTED CGRP ANTAGONISTS, PROCEDURE FOR PREPARATION AS WELL AS ITS USE AS A MEDICINAL PRODUCT
CO5700754A2 (en) PIPERAZINE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL AND PSYCHIATRIC DISEASES
CO4930259A1 (en) DERIVATIVES 6,6-HETEROBICICLICOS SUBSTITUTED AND PHARMACEUTICAL COMPOSITIONS THAT CONTAIN THEM
CY1105811T1 (en) TAXON AMPLIFIER COMPOUNDS
ES2183331T3 (en) SULFAMIDA-METALOPROTEASA INHIBITORS.
CY1109886T1 (en) New compounds as anti-inflammatory, immunomodulatory and anti-hypoplastic agents
UY28848A1 (en) SELECTED CGRP ANTAGONISTS, PROCEDURES FOR THEIR PREPARATION, AND THEIR EMPLOYMENT AS MEDICATIONS
ES2031876T3 (en) A PROCEDURE FOR THE PREPARATION OF 5,6-DIHYDRO-2- (SUBSTITUTED PHENYL) -1,2,4, -TRIAZIN-3,5 (2H, 4H) -DIONAS.
UY27851A1 (en) DIFENILAZETIDINONAS REPLACED IN RING, PROCEDURE FOR PREPARATION, MEDICATIONS UNDERSTANDING THESE COMPOUNDS AND THEIR USE.
SE0400043D0 (en) New compounds
CO5031250A1 (en) PHARMACEUTICAL COMPOUND
PA8587501A1 (en) BENZOXAZINONAS SUBSTITUTED AND USES OF THE SAME
UY26465A1 (en) ANTIPICORNAVIRAL COMPOUNDS AND COMPOSITIONS, THEIR PHARMACEUTICAL USES, AND MATERIALS FOR THEIR SYNTHESIS.
CO4600635A1 (en) PROCEDURES AND INTERMEDIATES TO PREPARE SUBSTITUTED CHROMANOL DERIVATIVES
CY1106396T1 (en) LINEAR OR CIRCULAR UREAS, METHOD OF THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS PREPARING THEM
AR028947A1 (en) NEW COMPOUNDS
UY26988A1 (en) NEW INDOLINONES REPLACED, ITS PREPARATION AND ITS USE AS MEDICINES.
DE60013994D1 (en) 1,2-disubstituted 1,4-dihydro-4-oxoquinoline compounds
UY27770A1 (en) IMIDAZOLINILMETIL ARALQUILSULFONAMIDAS